By Michele Maatouk
Date: Wednesday 07 Jan 2026
(Sharecast News) - IP Group slumped on Wednesday after it said portfolio company Pulmocide has decided to end the Phase 3 study of its opelconazole product for the treatment of invasive pulmonary aspergillosis (IPA).
| Transaction in Own Shares | 07-Jan-2026 | 18:25 | RNS |
| Director/PDMR Shareholding | 07-Jan-2026 | 18:15 | RNS |
| Greencore Group | 07-Jan-2026 | 18:00 | RNS |
| Standard form for notification of major holdings | 07-Jan-2026 | 17:49 | RNS |
| Transaction in Own Shares | 07-Jan-2026 | 17:45 | RNS |
| Bridgepoint buys Interpath from HIG Capital in £... | 05-Jan-2026 | Times |
| Next eyes lift in profits as sales grow | 31-Dec-2014 | The Herald |
| Special dividend from Next after online sale boost | 31-Dec-2014 | The Scotsman |
| PartyPoker firm sounds revenues warning | 31-Dec-2014 | Guardian |
| Business Next Next emerges as a Christmas winner | 31-Dec-2014 | Guardian |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor:Babcock | 19-Dec-2014 | Telegraph |
| Questor:N Brown | 12-Dec-2014 | Telegraph |
| Questor :Victrex | 11-Dec-2014 | Telegraph |
| Questor :Aberdeen Asset Management | 03-Dec-2014 | Telegraph |
| Price | 5,476.76 |
| Change Today | -33.72 |
| % Change | -0.61 % |
| 07-Jan-26 Close | 5,476.76 |
You are here: research